Description: Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial, which is a combined oral contraceptive; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a solution for treating menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it offers NEXTSTELLIS, an oral contraceptive pill. In addition, the company provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. Mithra Pharmaceuticals SA was founded in 1999 and is headquartered in Liège, Belgium.
Home Page: www.mithra.com
Rue Saint-Georges 5
Liège,
4000
Belgium
Phone:
32 4 349 28 22
Officers
| Name | Title |
|---|---|
| Mr. Leon Van Rompay | Chief Exec. Officer |
| Mr. Christophe Marechal | Chief Financial Officer |
| Dr. Graham K. Dixon Ph.D. | Chief Scientific Officer |
| Mr. Benoit Mathieu | Group Investor Relations Mang. |
| Mr. Cedric Darcis | Chief Legal Officer |
| Fanny Storms | Compliance Officer |
| Ms. Maud Vanderthommen | Group Communication Mang. |
| Ms. Laurence Schyns | Chief HR Officer |
| Mr. Jean-Manuel Fontaine | Chief Commercial & External Affairs Officer |
| Prof. Jean-Michel Foidart M.D., Ph.D. | Pres of the Scientific Advisory Board & Exec. Director |
Exchange: BR
Country: BE : Belgium
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 1.3161 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.8702 |
| Price-to-Sales TTM: | 9.9507 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 300 |